Connection

Alicia Jenkins to Diabetes Mellitus, Type 2

Back to Details
This is a "connection" page, showing publications Alicia Jenkins has written about Diabetes Mellitus, Type 2.
Alicia Jenkins
Connection Strength
4.476
Diabetes Mellitus, Type 2
  1. Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Sci Rep. 2021 09 21; 11(1):18708.
    View in: PubMed
    Score: 0.409
  2. Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. J Clin Endocrinol Metab. 2020 10 01; 105(10).
    View in: PubMed
    Score: 0.382
  3. Biomarkers in Diabetic Retinopathy. Rev Diabet Stud. 2015 Spring-Summer; 12(1-2):159-95.
    View in: PubMed
    Score: 0.268
  4. Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. J Diabetes Complications. 2014 May-Jun; 28(3):353-9.
    View in: PubMed
    Score: 0.240
  5. Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Res Clin Pract. 2012 Jan; 95(1):e17-9.
    View in: PubMed
    Score: 0.206
  6. Coated-platelet levels in patients with Type 1 and with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008 Aug; 81(2):e8-10.
    View in: PubMed
    Score: 0.163
  7. 'Lipoproteins, glycoxidation and diabetic angiopathy'. Diabetes Metab Res Rev. 2004 Sep-Oct; 20(5):349-68.
    View in: PubMed
    Score: 0.125
  8. Optimal Frequency of Retinopathy Screening in Adolescents With Type 1 Diabetes: Markov Modeling Approach Based on 30 Years of Data. Diabetes Care. 2022 10 01; 45(10):2383-2390.
    View in: PubMed
    Score: 0.110
  9. Vitamin D Levels During Pregnancy Are Associated With Offspring Telomere Length: A Longitudinal Mother-Child Study. J Clin Endocrinol Metab. 2022 08 18; 107(9):e3901-e3909.
    View in: PubMed
    Score: 0.109
  10. Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy. Intern Med J. 2022 04; 52(4):676-679.
    View in: PubMed
    Score: 0.106
  11. Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy. Diabetes Res Clin Pract. 2022 Apr; 186:109835.
    View in: PubMed
    Score: 0.106
  12. Shortened Leukocyte Telomere Length Is Associated With Glycemic Progression in Type 2 Diabetes: A Prospective and Mendelian Randomization Analysis. Diabetes Care. 2022 03 01; 45(3):701-709.
    View in: PubMed
    Score: 0.105
  13. Relative leucocyte telomere length is associated with incident end-stage kidney disease and rapid decline of kidney function in type 2 diabetes: analysis from the Hong Kong Diabetes Register. Diabetologia. 2022 02; 65(2):375-386.
    View in: PubMed
    Score: 0.103
  14. Skin autofluorescence is associated with progression of kidney disease in type 2 diabetes: A prospective cohort study from the Hong Kong diabetes biobank. Nutr Metab Cardiovasc Dis. 2022 02; 32(2):436-446.
    View in: PubMed
    Score: 0.103
  15. Skin autofluorescence is associated with higher risk of cardiovascular events in Chinese adults with type 2 diabetes: A prospective cohort study from the Hong Kong Diabetes Biobank. J Diabetes Complications. 2021 10; 35(10):108015.
    View in: PubMed
    Score: 0.101
  16. The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diab Vasc Dis Res. 2021 Jul-Aug; 18(4):14791641211032547.
    View in: PubMed
    Score: 0.101
  17. Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Res Clin Pract. 2020 Nov; 169:108450.
    View in: PubMed
    Score: 0.095
  18. Shortened Relative Leukocyte Telomere Length Is Associated With Prevalent and Incident Cardiovascular Complications in Type 2 Diabetes: Analysis From the Hong Kong Diabetes Register. Diabetes Care. 2020 09; 43(9):2257-2265.
    View in: PubMed
    Score: 0.094
  19. Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes Obes Metab. 2020 08; 22(8):1388-1396.
    View in: PubMed
    Score: 0.093
  20. Associations between circulating inflammatory markers, diabetes type and complications in youth. Pediatr Diabetes. 2019 12; 20(8):1118-1127.
    View in: PubMed
    Score: 0.089
  21. Serum pigment epithelium-derived factor: Relationships with cardiovascular events, renal dysfunction, and mortality in the Veterans Affairs Diabetes Trial (VADT) cohort. J Diabetes Complications. 2019 10; 33(10):107410.
    View in: PubMed
    Score: 0.088
  22. Effect of a high-egg diet on cardiometabolic risk factors in people with type 2 diabetes: the Diabetes and Egg (DIABEGG) Study-randomized weight-loss and follow-up phase. Am J Clin Nutr. 2018 06 01; 107(6):921-931.
    View in: PubMed
    Score: 0.081
  23. Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clin Chem. 2017 Jul; 63(7):1261-1270.
    View in: PubMed
    Score: 0.076
  24. HDL as a Target for Glycemic Control. Curr Drug Targets. 2017; 18(6):651-673.
    View in: PubMed
    Score: 0.074
  25. Liberal Glycemic Control in Critically Ill Patients With Type 2 Diabetes: An Exploratory Study. Crit Care Med. 2016 09; 44(9):1695-703.
    View in: PubMed
    Score: 0.072
  26. Muscle grip strength predicts incident type 2 diabetes: Population-based cohort study. Metabolism. 2016 06; 65(6):883-92.
    View in: PubMed
    Score: 0.070
  27. Opposite associations between alanine aminotransferase and ?-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism. 2016 May; 65(5):783-793.
    View in: PubMed
    Score: 0.069
  28. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Sep; 58(9):2035-44.
    View in: PubMed
    Score: 0.066
  29. Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):521-8.
    View in: PubMed
    Score: 0.064
  30. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Mar; 58(3):464-73.
    View in: PubMed
    Score: 0.064
  31. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2014 Nov; 57(11):2296-303.
    View in: PubMed
    Score: 0.063
  32. Peroxisome proliferator-activated receptor a protects capillary pericytes in the retina. Am J Pathol. 2014 Oct; 184(10):2709-20.
    View in: PubMed
    Score: 0.062
  33. HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes. Diabetes Care. 2014 Aug; 37(8):2351-8.
    View in: PubMed
    Score: 0.061
  34. Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. J Diabetes Complications. 2013 Nov-Dec; 27(6):627-32.
    View in: PubMed
    Score: 0.058
  35. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2012 Dec; 97(12):4701-8.
    View in: PubMed
    Score: 0.055
  36. Serum apolipoproteins are associated with systemic and retinal microvascular function in people with diabetes. Diabetes. 2012 Jul; 61(7):1785-92.
    View in: PubMed
    Score: 0.053
  37. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012 Feb; 35(2):218-25.
    View in: PubMed
    Score: 0.052
  38. Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages. Arterioscler Thromb Vasc Biol. 2011 May; 31(5):1192-200.
    View in: PubMed
    Score: 0.049
  39. Is nuclear magnetic resonance lipoprotein subclass related to diabetic retinopathy? The multi-ethnic study of atherosclerosis (MESA). Diab Vasc Dis Res. 2009 Jan; 6(1):40-2.
    View in: PubMed
    Score: 0.042
  40. NMR-determined lipoprotein subclass profile predicts type 2 diabetes. Diabetes Res Clin Pract. 2009 Jan; 83(1):132-9.
    View in: PubMed
    Score: 0.042
  41. Cardiovascular risk factors in pre-pubertal Malays: effects of diabetic parentage. Diabetes Res Clin Pract. 2007 Apr; 76(1):119-25.
    View in: PubMed
    Score: 0.036
  42. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003 Feb; 52(2):453-62.
    View in: PubMed
    Score: 0.028
  43. Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling. J Invest Dermatol. 2014 Jun; 134(6):1725-1734.
    View in: PubMed
    Score: 0.015
  44. Normalized NEFA dynamics during an OGTT after islet transplantation. Transplantation. 2012 Oct 15; 94(7):e49-51.
    View in: PubMed
    Score: 0.014
  45. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2010 Apr; 30(4):766-72.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.